TY - JOUR
T1 - Efficacy of natural antimicrobial peptides versus peptidomimetic analogues
T2 - a systematic review
AU - Hellewell, Lauren
AU - Gilani, Nakisa Malek
AU - Stanton, Christopher James
AU - Pelligand, Ludovic
AU - Franzyk, Henrik
AU - Guardabassi, Luca
AU - Good, Liam
PY - 2022
Y1 - 2022
N2 -
Aims: This systematic review was carried out to determine whether synthetic peptidomimetics exhibit significant advantages over antimicrobial peptides (AMPs) in terms of
in vitro potency. Structural features - molecular weight, charge and length - were examined for correlations with activity.
Methods: Original research articles reporting minimum inhibitory concentration (MIC) values against
Escherichia coli, indexed until 31 December 2020, were searched in PubMed/ScienceDirect/Google Scholar and evaluated using mixed-effects models.
Results:
In vitro antimicrobial activity of peptidomimetics resembled that of AMPs. Net charge significantly affected MIC values (p < 0.001) with a trend of 4.6% decrease for increments in charge by +1.
Conclusion: AMPs and antibacterial peptidomimetics exhibit similar potencies, providing an opportunity to exploit the advantageous stability and bioavailability typically associated with peptidomimetics.
AB -
Aims: This systematic review was carried out to determine whether synthetic peptidomimetics exhibit significant advantages over antimicrobial peptides (AMPs) in terms of
in vitro potency. Structural features - molecular weight, charge and length - were examined for correlations with activity.
Methods: Original research articles reporting minimum inhibitory concentration (MIC) values against
Escherichia coli, indexed until 31 December 2020, were searched in PubMed/ScienceDirect/Google Scholar and evaluated using mixed-effects models.
Results:
In vitro antimicrobial activity of peptidomimetics resembled that of AMPs. Net charge significantly affected MIC values (p < 0.001) with a trend of 4.6% decrease for increments in charge by +1.
Conclusion: AMPs and antibacterial peptidomimetics exhibit similar potencies, providing an opportunity to exploit the advantageous stability and bioavailability typically associated with peptidomimetics.
U2 - 10.4155/fmc-2022-0160
DO - 10.4155/fmc-2022-0160
M3 - Review
C2 - 36421051
VL - 14
SP - 1899
EP - 1921
JO - Future Medicinal Chemistry
JF - Future Medicinal Chemistry
SN - 1756-8919
IS - 24
ER -